Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2023-03-30 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于前沿生物药业（南京）股份有限公司使用部分闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the use of idle raised funds by Qianyan Biopharmaceutical (Nanjing) Co., Ltd. It references regulatory guidelines on the management and use of raised funds, details the amount and purpose of the funds raised, and confirms compliance with relevant regulations. The document is not a full financial report but a formal verification or audit opinion related to the use of funds. It does not contain comprehensive financial statements or quarterly/yearly financial data. The document length is 3126 characters, which is relatively short and focused on a specific regulatory compliance matter. This fits the category of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to regulatory compliance, excluding full annual or interim reports. Q1 2023
2023-03-30 Chinese
前沿生物2022年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's 2022 annual fundraising capital deposit and usage situation, including audited capital amounts, usage breakdowns, compliance with regulatory guidelines, and auditor and sponsor opinions. It references specific regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange, and includes detailed financial figures and project investment progress. The document is lengthy (over 11,000 characters) and contains substantive financial data and analysis related to capital raised and its management. This matches the description of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. It is not an announcement of a report publication, nor a full annual report or interim report, but a specialized report on fundraising capital usage and management.
2023-03-30 Chinese
前沿生物独立董事对公司2022年对外担保情况的专项说明和独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's external guarantees for the year 2022. It references regulatory guidelines from the China Securities Regulatory Commission and provides a compliance opinion on the external guarantees. The document is short (454 characters) and focuses on a specific governance-related matter rather than a full financial report or announcement. It does not contain financial statements or detailed financial data, nor is it an announcement of a report publication. This fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2023-03-30 Chinese
前沿生物2022年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2022年度董事会审计委员会履职情况报告" which translates to "2022 Annual Board Audit Committee Performance Report." It details the audit committee's activities, meetings, supervision of external auditors, internal audit guidance, review of financial reports, internal control evaluation, and coordination with auditors. The document is a report on the audit committee's work and oversight related to auditing and internal controls for the year 2022. It is not the full annual report or financial statements but a standalone audit-related report. The document length is 2506 characters, which is relatively short but contains substantive content about audit committee activities rather than just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2022
2023-03-30 Chinese
前沿生物监事会关于终止实施2021年限制性股票激励计划的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's verification opinion regarding the termination of a 2021 restricted stock incentive plan. It references relevant laws and regulations and concludes with the board's agreement to terminate the plan. The content is a formal opinion or statement related to corporate governance and incentive plan management, not a financial report, earnings release, or capital update. It does not announce voting results, changes in management, or share transactions. It is a regulatory compliance-related statement. Given the short length and nature of the document, it fits best under Regulatory Filings (RNS) as a compliance announcement that does not fit other specific categories.
2023-03-30 Chinese
前沿生物独立董事关于第三届董事会第七次会议相关事项的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a formal opinion from independent directors regarding the reappointment of the company's audit firm for the 2023 fiscal year. It references the audit firm and the upcoming board meeting agenda but does not contain any financial statements, audit results, or detailed audit reports. The document is short (639 characters) and serves as a pre-approval or endorsement related to audit matters, not the audit report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official regulatory announcement related to audit firm appointment rather than the audit report or annual report itself.
2023-03-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.